Senti Biosciences (NASDAQ:SNTI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Senti Biosciences (NASDAQ:SNTI) to a sell rating in a research note issued to investors on Saturday.

Other research analysts also recently issued reports about the company. Leerink Partners started coverage on Senti Biosciences in a research report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price target for the company. Leerink Partnrs upgraded shares of Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. Finally, Chardan Capital boosted their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Senti Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Senti Biosciences Price Performance

Senti Biosciences stock opened at $1.21 on Friday. Senti Biosciences has a fifty-two week low of $1.19 and a fifty-two week high of $5.44. The firm has a fifty day moving average price of $1.93 and a two-hundred day moving average price of $1.92. The firm has a market cap of $31.81 million, a price-to-earnings ratio of -0.36 and a beta of 2.08.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, sell-side analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.

Hedge Funds Weigh In On Senti Biosciences

A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in Senti Biosciences in the 3rd quarter valued at $117,000. Geode Capital Management LLC lifted its holdings in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the period. Armistice Capital LLC acquired a new stake in shares of Senti Biosciences in the 2nd quarter valued at $1,883,000. Heights Capital Management Inc. bought a new stake in shares of Senti Biosciences in the 1st quarter worth about $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences in the 1st quarter worth about $2,984,000. 25.70% of the stock is owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.